INMB Inmune Bio (INMB) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001711754
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
48
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · $43.4K priced
Inmune Bio insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Inmune Bio, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 11 earlier Form 4 trades (code P or S) here by this insider (5 buys, 6 sales), the last on Sep 12, 2024.
- +31.2% median (+18.7% mean) 90-day return after 5 previous buys.
- The trade is 0.8% of the 1,285,869 shares held after it.
- 1 other insider bought within 30 days.
- 48 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Moss David J bought about $52.9K of INMB on Sep 30, 2024; 1 other insider bought within 30 days and 48 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (2 buys, 5 sales), the last on Apr 19, 2024.
- +19.9% median (+19.9% mean) 90-day return after 2 previous buys.
- The trade is 1.0% of the 1,554,106 shares held after it.
- 1 other insider bought within 30 days.
- 48 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Tesi Raymond Joseph bought about $98.1K of INMB on Sep 12, 2024; 1 other insider bought within 30 days and 48 funds added in the latest 13F quarter.Context
- 10 earlier Form 4 trades (code P or S) here by this insider (4 buys, 6 sales), the last on Apr 19, 2024.
- +34.5% median (+27.8% mean) 90-day return after 4 previous buys.
- The trade is 0.6% of the 1,275,869 shares held after it.
- 1 other insider bought within 30 days.
- 48 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Moss David J bought about $49.1K of INMB on Sep 12, 2024; 1 other insider bought within 30 days and 48 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Apr 19, 2024.
- +1.9% median (+18.6% mean) 90-day return after 3 previous buys.
- The trade is 7.0% of the 71,603 shares held after it.
- No other insider bought within 30 days.
- 48 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Juda Scott bought about $36.4K of INMB on Jun 25, 2024; 48 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (3 buys, 6 sales), the last on Mar 17, 2023.
- +37.9% median (+36.4% mean) 90-day return after 3 previous buys.
- The trade is 1.4% of the 1,268,179 shares held after it.
- 3 other insiders bought within 30 days.
- 48 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO, Treasurer & Secretary Moss David J bought about $150.0K of INMB on Apr 19, 2024, the largest insider purchase at the company on our record; 3 other insiders bought within 30 days and 48 funds added in the latest 13F quarter.33 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
48 funds bought in last quarter
below 54% of Pharma & Biotech
Revenue
+257.1% year over year
more than 91% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
11.4% of the float short (float per yahoo 2026-10-26) · 7.0 days to cover · settled 2026-09-30
more than 70% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch INMB
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-18.0%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns INMB: institutional holders (13F)
13F holdings, latest reported quarter
706,424 sh
$1.2M
662,218 sh
$1.1M
311,613 sh
$507.9K
212,995 sh
$347.2K
190,215 sh
$310.3K
Congress trades in INMB
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
INMB planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
INMB mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$133.0K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$9.1K position · as of 2026-06-30
0.0%
VANGUARD RUSSELL 2000 GROWTH INDEX FUND
$27.6K position · as of 2026-05-31
0.0%
VANGUARD RUSSELL 2000 INDEX FUND
$160.3K position · as of 2026-05-31
0.0%
ProShares Russell 2000 High Income ETF
$1.5K position · as of 2026-05-31
0.0%
Small Cap Index Fund
$10.1K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
7 registered trials, 0 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Phase 1
0 active
3
Phase 2
0 active
2
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 48 funds added last quarter. Each figure is a federal filing, dated the day it went public.
INMB financials
Revenue growth
+257.1%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$50.0K
four quarters, 2025-01-01 to 2025-12-31
Revenue, TTM INMB
| FY Dec 2025 | $50.0K |
| FY Dec 2024 | $14.0K |
| FY Dec 2023 | $155.0K |
| FY Dec 2022 | $374.0K |
| FY Dec 2021 | $181.0K |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | $0 |
| Sep 2025 | $0 |
| Jun 2025 | $0 |
| Mar 2025 | $50.0K |
| Dec 2024 | $0 |
| Sep 2024 | $0 |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM INMB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM INMB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -$3.1M |
| Sep 2025 | -$5.6M |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
0.74x
LongTermDebt as filed 2025-06-30 (12 months older than the period end) (includes the current portion); equity 2026-06-30
Debt to equity INMB
| FY Dec 2025 | 0.64x |
| FY Dec 2024 | 0.47x |
| FY Dec 2023 | 0.33x |
| FY Dec 2022 | 0.24x |
| FY Dec 2021 | 0.19x |
| Jun 2026 | 0.74x |
| Mar 2026 | 0.76x |
| Dec 2025 | 0.64x |
| Sep 2025 | 0.59x |
| Jun 2025 | 0.52x |
| Mar 2025 | 0.51x |
| Dec 2024 | 0.47x |
| Sep 2024 | 0.32x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-1.00x
TTM operating cash flow over LongTermDebt as filed 2025-06-30 (12 months older than the period end) (includes the current portion)
Cash flow to debt INMB
| FY Dec 2025 | -1.51x |
| FY Dec 2024 | -2.22x |
| FY Dec 2023 | -0.96x |
| FY Dec 2022 | -1.54x |
| FY Dec 2021 | -1.90x |
| Jun 2026 | -1.00x |
| Mar 2026 | -1.28x |
| Dec 2025 | -1.51x |
| Sep 2025 | -2.04x |
| Jun 2025 | -2.15x |
| Mar 2025 | -2.18x |
| Dec 2024 | -2.22x |
| Sep 2024 | -2.06x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-75.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity INMB
| FY Dec 2025 | -165.4% |
| FY Dec 2024 | -121.0% |
| FY Dec 2023 | -61.6% |
| FY Dec 2022 | -38.9% |
| FY Dec 2021 | -51.0% |
| Jun 2026 | -75.1% |
| Mar 2026 | -169.0% |
| Dec 2025 | -165.4% |
| Sep 2025 | -155.5% |
| Jun 2025 | -170.2% |
| Mar 2025 | -140.6% |
| Dec 2024 | -121.0% |
| Sep 2024 | -99.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-57.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets INMB
| FY Dec 2025 | -127.9% |
| FY Dec 2024 | -87.0% |
| FY Dec 2023 | -43.2% |
| FY Dec 2022 | -30.0% |
| FY Dec 2021 | -43.2% |
| Jun 2026 | -57.3% |
| Mar 2026 | -131.0% |
| Dec 2025 | -127.9% |
| Sep 2025 | -115.6% |
| Jun 2025 | -123.0% |
| Mar 2025 | -96.2% |
| Dec 2024 | -87.0% |
| Sep 2024 | -71.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital INMB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-80.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed INMB
| FY Dec 2025 | -168.4% |
| FY Dec 2024 | -120.3% |
| FY Dec 2023 | -54.4% |
| FY Dec 2022 | -31.2% |
| FY Dec 2021 | -43.4% |
| Jun 2026 | -80.7% |
| Mar 2026 | -172.1% |
| Dec 2025 | -168.4% |
| Sep 2025 | -158.2% |
| Jun 2025 | -169.1% |
| Mar 2025 | -140.1% |
| Dec 2024 | -120.3% |
| Sep 2024 | -95.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing INMB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$30.8M
market value at close 2026-10-23 on 2026-08-06 shares, plus LongTermDebt as filed 2025-06-30 (12 months older than the period end) (includes the current portion), minus cash 2025-12-31
Enterprise value INMB
| FY Dec 2025 | $31.7M |
| FY Dec 2024 | $97.6M |
| FY Dec 2023 | $179.6M |
| FY Dec 2022 | $76.3M |
| FY Dec 2021 | $122.2M |
| Jun 2026 | $33.6M |
| Mar 2026 | $20.3M |
| Dec 2025 | $31.7M |
| Sep 2025 | $42.3M |
| Jun 2025 | $35.2M |
| Mar 2025 | $174.7M |
| Dec 2024 | $97.6M |
| Sep 2024 | $85.6M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield INMB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing INMB
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $50.0K | $14.0K | $155.0K | $374.0K |
| Operating income | -$47.4M | -$42.6M | -$29.7M | -$26.0M |
| Net income | -$46.0M | -$42.0M | -$30.0M | -$27.3M |
| EPS (diluted) | -1.86 | -2.11 | -1.67 | -1.52 |
| Operating cash flow | -$22.6M | -$33.4M | -$12.0M | -$22.7M |
| Cash | $24.8M | $20.9M | $35.8M | $52.2M |
| Long-term debt | n/a | $15.0M | n/a | $9.7M |
SEC XBRL, fiscal years, as known on 2026-10-27
INMB Stock Sonar score 5/7 axes
Find similar shapesCompareINMB ranks highest on growth (91st percentile) and institutional and government (46th), and lowest on risk and compliance (18th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
